Posted by Michael Wonder on 04 Nov 2021
Lipocine announces FDA grants fast track designation to LPCN 1144 for treatment of non-cirrhotic NASH
4 November 2021 - Lipocine today announced that the U.S. FDA has granted fast track designation to LPCN 1144 as a treatment for non-cirrhotic non-alcoholic steatohepatitis.
LPCN 1144, an oral pro-drug of bioidentical testosterone, was recently studied in the Liver Fat intervention with oral Testosterone (LiFT) Phase 2 paired biopsy clinical study in patients with confirmed non-alcoholic steatohepatitis.
